| INTRODUCTION
Atrial fibrillation (AF) is the commonest arrhythmia encountered in clinical practice, according for significant morbidity and mortality through the development of cerebrovascular accidents and heart failure. Recently, increased inflammation and oxidative stress have been implicated in the pathogenesis of atrial remodeling, which is thought to underlie increased vulnerability to tachy-arrhythmias. 1 Diabetes mellitus (DM) is an independent risk factor of AF, and both share common pathophysiological mechanisms. [2] [3] [4] Diabetes-related changes in metabolic function, as well as in inflammatory and oxidative status, create a favorable substrate for sustaining AF.
Pioglitazone, a peroxisome proliferator-activated receptor (PPAR)-γ activator with anti-inflammatory properties, may produce beneficial effects by protecting against pathological remodeling in the atria. [5] [6] [7] In this study, the effects of diabetes on structural and ion current remodeling were examined and correlated with vulnerability to AF using an alloxan-induced diabetes model in rabbits. In the DM group, alloxan monohydrate (Sigma, Saint Louis, USA) was dissolved in sterile normal saline to achieve a concentration of 5% (W/V), and 150 mg/kg was immediately administered intravenously via the marginal ear vein. Diabetes was confirmed 48 hours later by blood glucose levels of ≥14 mmol/L (single measurement) or ≥11 mmol/L (two measurements). Blood glucose concentration was monitored weekly thereafter using a glucometer Optium Xceed (Abbott, Bedford, USA) for 8 weeks.
| MATERIAL AND METHODS

| Study design and preparation of the rabbit DM model
This
| Hemodynamic and echocardiographic examination
After 8 weeks, the right carotid artery of the rabbit was surgically isolated with a median neck incision. A cannula was inserted into the right carotid artery to monitor and record aortic systolic and dias- 
| Electrophysiological studies
A median sternotomy was performed, and the heart was quickly excised and placed in the perfusion fluid at 4°C. period (AERP) was determined using S1S2 stimulation delivering successively premature S2 extra-stimuli and was defined as the longest S1S2 interval that failed to elicit an atrial deflection. AF vulnerability was tested using burst pacing (50 ms) delivered for 1s and the S1S2 stimulation method. AF was induced at three different sites in each heart, with five repeats performed at each site. Thus, in eight rabbits, a total of 240 attempts to induce AF were performed in each group.
The appearance of AF was defined as a rapid, irregular atrial response, lasting for longer than 1000 ms.
| Whole-cell patch-clamp studies
For whole-cell patch-clamp studies, the experimental procedures were conducted in accordance to previously described methodology.
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The LA was used for the isolation of a single myocyte by 15 
| Histological examination
After electrophysiological studies, the left atria were isolated, placed in 4% paraformaldehyde, embedded in paraffin, and cut into 4-μm cross sections for histological analysis. Sirius-red (SR) (Sigma) stain was used to evaluate atrial interstitial fibrosis (n=8 for each group).
Micrographs were digitized using Photoshop 7.0 (Adobe, San Jose, CA), and areas of fibrosis and collagen volume fraction (CVF) were analyzed using Image Pro Plus 4.5 Scion image software (Scion co., Frederick, MD).
| Western blot analysis
Proteins of LA tissue were extracted using a total protein extraction buffer. An equal amount of protein was loaded onto a 15% SDS denaturing polyacrylamide gel, separated by electrophoresis, transferred onto PVDF membrane (Merck Millipore, USA), and incubated with the specific primary antibody overnight at 4°C. Protein levels of extracellular signal-regulated kinase 2 (ERK2), phosphorylation ERK (pERK), transforming growth factor beta 1 (TGFβ1), Toll-like receptor 4 (TLR4), nuclear factor-κB p50 (NF-κB p50), and heat-shock protein 70 (HSP70) were expressed as ratio to levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The membranes were then washed and subsequently incubated with the secondary antibody conjugated to horseradish peroxidase (HRP). Protein was visualized using enhanced chemiluminescence. The anti-GAPDH and anti-ERK2, pERK, TGF-β1, TLR4, NF-κB p50, and HSP70 antibodies were purchased from Abcam Inc (USA). The resulting bands were quantified using GeneTools software (Gene, USA).
| Statistical analysis
Continuous variables were expressed as mean±1 SD, and categorical variables were presented as percentages. The Kolmogorov-Smirnov test was used to test the distribution of continuous variables. Variables with a normal distribution were compared using the one-way ANOVA, and those without normal distribution were compared using the nonparametric Kruskal-Wallis test. The differences in the incidence of AF were analyzed by chi-square test. A two-tailed P<.05 was considered significant.
| RESULTS
| Baseline characteristics
As shown in Table 1 , glucose level was significantly lower and insulin levels were higher in the control group (CN) when compared to the diabetes group, whether with or without pioglitazone treatment at low or high dose (4 and 8 mg/day/kg, respectively, both P<.01). No significant differences of these parameters were observed between the DM group, DM with low-dose pioglitazone treatment, and DM with high-dose pioglitazone groups (P>.05). Figure 1 shows two examples of AF induced by burst pacing and S1S2 pacing. (Figure 2A ). These repolarization abnormalities can be explained by alterations in ion channel function.
| Hemodynamic and echocardiographic studies
Thus, I CaL and I Na densities were determined, with peak current expressed as a function of the threshold potential (TP) ( Figure 2B ,C).
For I CaL , depolarizing pulses (200 ms) from an HP of −40 mV to voltages ranging from −50 mV to +60 mV elicited I CaL . I Na was measured upon 50-ms pulses from an HP of −90 mV to voltages ranging from −80 mV to +60 mV. DM increased I CaL and decreased I Na densities, and these changes were attenuated by pioglitazone (P<.05).
Although I Na density decreased in the DM group, the shape of the I-V curve was not changed. I Na was significantly reduced at voltages ranging from −60 mV to +20 mV. 
| Histological and protein expression studies
F I G U R E 1 Example of AF induced by burst pacing (A). Example of AF induced by S1S2 pacing (B)
in protein expression levels were prevented by pioglitazone treatment whether at a low or high dose (Figure 4 ).
| DISCUSSION
In this study, the potential protective effects of pioglitazone on atrial remodeling were examined in diabetic rabbits. Our results demonstrated that pioglitazone suppressed AF inducibility and abolished arrhythmic substrate by reversing both electrophysiological and structural remodeling. Higher levels of inflammation and oxidative stress have been demonstrated in chronic hyperglycemia. The therapeutic effects of pioglitazone may be due to its direct effects on blood insulin and glucose levels, but also its anti-inflammatory and antioxidant properties. In experimental type 2 diabetes models, these two effects could not be separated. In our experiments, pioglitazone exerted antiarrhythmic actions and associated pathological remodeling without affecting blood insulin or glucose levels.
| Diabetes, structural and electrophysiological remodeling
Recent epidemiological studies have suggested that DM generates a pro-arrhythmic substrate for the development of AF.
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Kato et al. 15 showed that atrial structural remodeling in the form of extensive interstitial fibrosis is an important mechanism. Such fibrotic change is partly dependent on activation of inflammatory and oxidative stress pathways, which are thought to underlie both DM and AF. In keeping with previous findings, 16 our current experimental data showed that increased interatrial conduction times substrate. 17, 18 From our data, although prolonged AERPs were observed in some atrial sites, AERP dispersion (AERPD) was markedly increased in DM rabbits. This would in turn promote the development of undirectional conduction block and therefore reentry. AERPD was markedly increased in DM rabbits suggesting that heterogeneity of atrial repolarization is another possible arrhythmogenesis of DM-related atrial electrical remodeling. These system-level changes were explicable by altered conductances of ion channels. Thus, reduced I Na and increased I CaL densities in the atria were present. We speculate rabbits suffering from DM (with greatest I CaL ) may be more easily subjected to atrial myocardial calcium overload, and our results revealed I CaL densities increased, so calcium overload has been suggested to be an important mechanism in the pathogenesis of AF in our study. Additionally, DM increased fibrosis-related TGFβ1 and pERK proteins in rabbit atria. Thus, this study provides pathophysiological insights for the mechanisms of atrial electrical and structural remodeling in the setting of DM.
T A B L E 3 Electrophysiological studies measurements
| Antidiabetic medications and their effects on atrial remodeling
Novel therapeutic interventions targeting inflammation and oxidative stress can potentially ameliorate atrial arrhythmic substrate. 6 Several nonion channel blocking agents such as statins, 19, 20 reninangiotensin pathway inhibitors, 21 n-3 fatty acids, 22 and several antioxidant drugs [23] [24] [25] [26] may possess favorable pleiotropic effects on AF.
We have previously demonstrated that TZDs, a class of PPAR-γ activators, may have potential benefits for AF prevention. 27 TZDs are insulin-sensitizing agents used in diabetes mellitus. 28 Experimental and clinical data [29] [30] [31] [32] [33] indicate that TZDs can prevent cytokinemediated increase in oxidative stress and reduce the release or activation of several inflammatory mediators, such as C-reactive protein (CRP), nuclear factor-κB (NF-κB), tumor necrosis factor-α (TNF-α), interleukin (IL)-2,-6,-8, matrix metalloproteinases (MMPs). Moreover, they can prevent cardiac fibrosis and concentric remodeling in heart failure. [34] [35] [36] Pioglitazone, a TZD, is shown to enhance the effects of circulating insulin without influencing glucose concentration in diabetes. In our animal model, pioglitazone had no effect on either glucose or insulin levels. Therefore, the observed effects on atrial remodeling could not be attributed to hypoglycemic or pro-insulin effects alone. 37 Instead, the present data complement recent experimental evidence demonstrating that an effect on electrophysiological remodeling. Thus, Kume et al. 5 indicated that pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. Xu et al. 38 showed that pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. Interestingly, Pacher et al. 39 indicated that APD 90 in single atrial cells of STZ-induced DM rats is prolonged compared to normal controls. I CaL is responsible for maintaining the AP plateau in atrial cardiomyocytes. Indeed, clinical and experimental studies consistently implicate downregulation of I CaL in AF maintenance. [40] [41] [42] By contrast, I Na is an important determinant of conduction velocity (CV) and plays a central role in AP generation and also determine the APD. 43 The decrease of I Na density and the associated gene expression may relate to intracellular calcium overload which is regarded a major mechanism of atrial electrical remodeling. 44 The slowing of interatrial conduction time, representing a decrease in conduction velocity, together with reduced AERP and AERP rate adaptation, is considered to be important factors in the initiation and maintenance of reentry.
In our study, eight weeks of hyperglycemia were sufficient to induce changes in ion channel expression in the atria. Pioglitazone decreased inducibility of AF and ameliorated the increase in IACT, decrease in AERP and AERPD and APD prolongation. These protective effects can be attributed to reversal of I CaL and I Na densities.
In addition to electrophysiological remodeling, structural remodeling also contributes to AF maintenance. Li et al. 45 showed that atrial fibrosis can lead to AF perpetuation. TGF-β1 has been recognized as a key mediator of fibrosis. Notably, TGF-β1 cascade plays a critical role in extracellular matrix (ECM) remodeling, whereby a disproportionate increase in collagen content and excessive ECM deposition are observed in response to enhanced TGF-β1 expression. 46 Western blot analysis in our model revealed that TGF-β1 is elevated in LA tissue of DM rabbits, correlating with the degree of interstitial fibrosis. Moreover, extracellular signal-regulated kinase 1/2 (ERK1/2) is a subfamily of mitogen-activated protein kinase (MAPK) that mediates signaling in atrial structural remodeling.
Goette et al. 47 indicated that ERK1/2 activation by phosphorylation (pERK1/2) mediates the fibrotic processes. Atrial enlargement can activate ERK pathway, decrease AERP, and increase AERPD, leading to increased susceptibility to AF. 48 Remarkably, Shimano et al. 49 indicated that pioglitazone attenuates TGF-β1-related atrial Gu et al. 6 showed pioglitazone inhibits angiotensin II-induced connective tissue growth factor expression and proliferation in atrial fibroblasts, which may be related to its inhibitory effects on TGF-β1/Smad2/3 and TGF-β1/TRAF6/TAK1 signaling pathways. In our study, pioglitazone treatment reduced LAD, cellular diameter, and cross-sectional area of LA, as well as protein expression of atrial tissue fibrosis indexes such as pERK and TGF-β1.
The antifibrotic effects of pioglitazone are associated with reduction in TNF-α signaling. 50 Our study found that pioglitazone can reduce cardiac damage and protect atrial tissue through its antiinflammatory actions. Activation of the TLR4/NF-κB signal transduction pathway in the rabbit DM model produced increases in protein expressions of pro-inflammatory cytokines. Pioglitazone can inhibit TLR4/NF-κB activity and TNF-α protein expression reducing the damage in atrial tissue. These data suggest that the TLR4/NF-κB pathway represents a novel mechanism by which DM mediates atrial structural remodeling and may provide useful therapeutic targets to reduce fibrosis.
| Study limitations and future studies
The following limitations should be acknowledged. Firstly, parameters of the LA, but not the right atrium (RA), were analyzed. The contributions of RA remodeling to AF are unknown. Secondly, the mechanisms underlying increasing AERP with higher heart rates were not examined. Thirdly, we could not evaluate the potential role of autonomic dysfunction using Langendorff-perfused rabbit heart model in vitro, because the heart rate in vitro cannot represent true autonomic function of the diabetic heart.
Future studies can investigate plasma or urinary markers of inflammation and oxidative stress, the protein expression of ion channels of I CaL and I Na , and the potential roles of diabetic autonomic neuropathy in mediating atrial remodeling.
| CONCLUSION
Our study demonstrated that DM provokes atrial interstitial fibrosis and ionic remodeling and increases vulnerability to AF rabbits.
Pioglitazone seems to exert beneficial effects in this setting, preventing atrial structural and electrical remodeling. More studies are needed in order to elucidate the exact clinical impact of pioglitazone as an upstream therapy in AF.
